HER2-Low Breast Cancers

CONCLUSIONS: The promising efficacy of novel HER2-targeted therapy in advanced HER2-low breast cancers has raised the possibility for changing the clinical interpretation of HER2 status in breast cancer to include a HER2-low category; however, the definition of HER2-low breast cancer, the corresponding reliable and accurate quantitative HER2 testing methodology, and the biology of HER2-low breast cancer remain poorly defined.PMID:34519765 | DOI:10.1093/ajcp/aqab117

Source: Clinical Breast Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Huina Zhang Hani Katerji Bradley M Turner David G Hicks Source Type: research